CIBER

CIBER-BBN Annual Conference 2019

In one month CIBER-BBN will celebrate its 13th Annual Conference on October 20 and 21 in Tarragona, at the Hotel Ciutat de Tarragona, Tarragona.

This year there several scientific sessions are planned about related leading issues with research topics of interest to CIBER-BBN. On Monday there will be three sessions centered in:

artificial intelligence and big data
gene editing and CRISPR and
liquid biopsy and point-ofcare.

Each of these sessions will include a plenary conference given by an expert
guest and two talks by BBN researchers, followed by an open debate.

The program will complete a session focused on the Singular Technical Scientific Infrastructure NANBIOSIS-ICTS.

On Tuesday, the four prizes will be awarded to the best scientific articles published by young researchers of CIBER-BBN during 2018 and there will be two other sessions on

nanobots and emerging drug administration technologies and
senescence and reprogramming

• Read More

Safe-N-Medtech kicks off in Bilbao

The Safe-N-MedTech European Project kcks off in Bibao to create an open innovation platform that accelerates the development of medical devices based on nanotechnologies.

During 2 and 3 of May took place in Bilbao, at the University of the Basque Country, the kick off meeting of the European project Safe-N-Medtech organized by Osteba, the HTA Unit of the Ministry of Health of the Basque Country (Spain) in collaboration with BIOPRAXIS-BIOKERALTY.

Safe-N-Medtech, counts with 28 partnerts coordinated by TECNAN (Navarran company with great experience in Nano products), together with BIOPRAXIS-BIOKERALTY, the research branch of the global health companies Keralty and Praxis. The new project is part of the Open Innovation Test Bed initiative (OITB) launched by the European Commission with the aim of accelerating the development of medical devices based on nanotechnologies in Europe and abroad. The project has a European funding of 15 million euros.

CIBER-BBN participates as a partner in the Safe-N-Medtech throught its Scientific Infraestructure, the ICTS NANBIOSIS. Several units of NANBIOSIS from CIBER-BBN and JUMISC wiil carry out some of the F/Q, in vivo and in vitro characterizations applied to pilot test cases, NANBIOSIS is the leader of WP3 Preclinical Research in nano-enabled MTs.

Society and clinical practice raise a growing demand for new biomaterials, ICTs, medical devices and in vitro diagnostics (Medical Technologies-MTs) based on micro and nanotechnologies. In addition to the challenge of time, new technologies are subject to other pressing factors, such as qualification, regulation, cost, biocompatibility and the need to be applicable throughout the world. Medical devices based on nanotechnologies can be applied in almost all medical areas, with an important presence in areas such as cancer, regenerative medicine, advanced therapies, neurology, cardiology, orthopedics and dentistry.

The initiative aims to build an open innovation platform to offer companies and reference laboratories the capabilities, knowledge, networks and services necessary for the development, testing, evaluation, improvement and exploitation of the market of medical devices and diagnostic based in nanotechnology. This platform will offer a multidisciplinary and market-oriented innovation approach for SMEs, health care providers and industries, accelerating the transfer to the market of these new medical devices. During the first years of project work, the partners will develop their services and test them in different case studies, so that, Safe-N-Medtech OITB can become a sustainable and competitive services platform for companies to accelerate their developments according to the necessary regulatory requirements and ensure the safety and effectiveness of their medical devices based on nanotechnologies.

• Read More

NANBIOSIS at CIBEREHD XI Annual Conferences

Jesús Izco, Coordinator of NANBIOSIS, has presented NANBIOSIS-ICTS at the XI annual Conference of CIBEREHD, which takes place from 27 to 28 November 2017 at the Hotel Barceló Sants in Barcelona.

Jesús Izco has explained the opportunities offered by the ICTS NANBIOSIS as a Platform for Research and Biomedical Innovation, giving examples of private-public collaboration in competitive calls in which NANBIOSIS has participated and explaining the design of the new Nanomedicine Cascade Characterization Service, in which NANBIOSIS is working on.

CIBEREHD (Center for biomedical research in liver and digestive diseases) is

The CIBER’s thematic area of Liver and Digestive Diseases (CIBEREHD) has the purpose of promoting and protecting health by furthering research. This work, whose scope includes both basic research and clinical and translational aspects, is based on the field of Liver and Digestive Diseases with the aim of innovating in the prevention of these diseases and promoting scientific and healthcare progress. At present the CIBEREHD is working on four corporate programmes:

P1. Mechanisms of liver damage/evolution into advanced cirrhosis and transplant.

P2. Gastrointestinal physiopathology: inflammatory illness and motility disorders.

P3. Epidemiology, prevention and treatment of viral hepatitis infection.

P4. Liver and Digestive Oncology

• Read More

NANBIOSIS in CIBER-BBN ANNUAL CONFERENCE 2017

CIBER-BBN will celebrate its 11th Annual Conference on November 13 and 14 in Santander. In these conference there will be a session dedicated to NANBIOSIS. Likewise, the annual meeting of the Scientific Technical Advisory Committee of NANBIOSIS will take place.

As in previous occasions, the meeting will serve to know the activity of NANBIOSIS, the Singular Technical Scientific Infrastructure (ICTS) of the CIBER-BBN and the Minimally Invasive Surgery Center Jesus Usón for the production and characterization of biomaterials, nanomaterials and devices up to its preclinical validation.

As a novelty, it will be presented at the conference, the new internal structure, generated by NANBIOSIS for the development of “turnkey” projects in which, taking advantage of the complementarity and experience of its Units, NANBIOSIS offers complete service packages, with added value, adapted to the client’s needs, for applications such as nanotherapeutic agents, regenerative medicine, medical and diagnostic devices, among others. Some of the packages that are already designed or in more advanced stages will be explained, among which stands out the service of characterization and cascade assessment of nanomaterials that includes the characterization of the physicochemical attributes, their biological properties in vitro (immunology, toxicology and efficacy), and its in vivo compatibility (immunology, toxicology and efficacy), using appropriate animal models, with the possibility of being subject to regulatory conditions of Good Laboratory Practices. Some success stories of these “turnkey” projects developed in NANBIOSIS will be shown.

On this occasion, in addition, it is planned a presentation of EATRIS , the European Infrastructure for the Translation of Medicine, with which NANBIOSIS has initiated a line of collaboration.

Since its launch in July 2015, NANBIOSIS has received more than 550 access requests through its website, with an average participation of some 80 competitive projects per year and with an annual income for its services of between 2 and 3 million euros. Among its users, there are more than 100 companies.

• Read More

NANBIOSIS presented at the 12th annual event of the ETPN

During the days 17-19 of October Malaga has hosted the 12th annual event of European Platform of Technology in Nanomedicine (ETPN), a European meeting of 200 experts in research and innovation in nanomedicine.

The meeting was organized by Bionand, the Spanish Platform of Nanomedicine (Nanomed Spain), the Institute of Nanoscience of Madrid (Imdea) and the Center for Biomedical Research Network in the area of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), partner of NANBIOSIS.

During the event, the ETPN General Assembly took place as well as parallel meetings of the specialized working groups on different scientific and cross-cutting aspects related to nanomedicine

In this framework, the ICTS NANBIOSIS has been presented by the Scientific Director of CIBER-BBN, Ramón Martínez Máñez, to the European Nanomedicine community.

EUROPEAN TECHNICAL PLATFORM OF NANOMEDICINE

The European Technology Platforms are a key element in the European field of innovation, associations born with the mission of sharing knowledge, mobilizing the actors involved and developing sector strategies, all based on the social challenges established by the European Commission and with the ultimate goal of its translation to the market.

The European Nanomedicine Technology Platform (ETPN) was created in 2005 by the European Commission and a group of experts from academia and industry who have since contributed to the publication of various strategic documents identifying the needs and the roadmaps for research in Nanomedicine in Europe. Its main objectives are to establish a clear strategic vision of the sector, to reduce the fragmentation of nanomedical research, to mobilize public and private investment, to identify priority areas, to promote innovation in nanobiotechnologies for medical use and to strengthen Europe’s competitiveness in this sector scientific and industrial level

Currently, the ETPN has more than 120 members from 25 countries, representing all actors involved in nanomedicine, such as academic institutions, research centers, small and medium enterprises, industry, public agencies, representatives of the platforms the European Commission itself, among others.

• Read More

NANBIOSIS: collaborative research opportunities for groups of CIBER consortia

Last week, Jesús Izco, coordinator of NANBIOSIS, presented to CIBER groups the capabilities of NANBIOSIS and the opportunities for collaboration with the ICTS. From these meetings emerged diverse expressions of interest on the part of the attending researchers.

On June 30, Jesús Izco was invited to present NANBIOSIS in the Annual Scientific Conference of CIBERES. He explained several investigations that are currently being developed in NANBIOSIS and can be applied in the diagnosis and therapy of respiratory diseases, such as the development of physical devices and tests that allow the detection of biomarkers, new protein carriers in the format of nanoparticles capable of recognizing cell receptors and being endocytosed in order to deliver drugs or toxins in target tissues, or non-viral vectors based on niosomes for pulmonary gene therapy (eg cystic fibrosis) by inhalation.

Also, on June 28, Dr. Izco participated in a meeting at the Carlos III Health Institute (Madrid) with the working group on lung cancer of CIBERONC about respiratory tract tumors. Jesús Izco presented both examples of the projects currently under development in the NANBIOSIS units with application to the detection and monitoring of lung cancer, such as PreDICT, and examples of results already published in this scientific area.

• Read More

Nanbiosis new ICTS incorporation

The new map of Scientific and Technological Infrastructures (ICTS), was updated by the Council for Science Policy, Technology and Innovation last 7^th of October, 2014, which incorporated The Integrated Infrastructure on Production and Characterization of Nanomaterials, Biomaterials and Systems in Biomedicine (NANBIOSIS) . The new ICTS is integrated by the CIBER-BBN and the Center for Minimally Invasive Surgery Jesus Uson (JUMISC).

Pablo Laguna, scientific director of the CIBER-BBN noted that “this recognition is the result of efforts of both institutions to try to provide research services of high quality and added value, usually high-cost equipment, which is available to the scientific community, giving them greater and better use and avoiding costly and not always necessary redundancies. Furthermore, the fact that these infrastructures are coordinated by experts in their subjects, makes the scope of these infrastructures to exceed the national territory to become an actor at international level “.

The research infrastructure is aimed at medical applications and tries to provide a complete service and easy access through a “single contact point”, which includes the design, production of biomaterials and nanomaterials characterization of these materials, tissues , medical and systems from a physical, chemical, functional, toxicological and biological point of view including preclinical validation.

NANBIOSIS’ Units are located in Zaragoza, Badajoz, Barcelona, Caceres, Madrid, Valencia and Álava. Provides personnel and cross-cutting equipment in all the units in which infrastructure is organized, with dedication to service to the entire scientific community.

The new Spanish map of ICTS has 29 infrastructures and has been updated taking into account criteria of highest scientific quality, technology and innovation, subjecting candidates to a rigorous process of independent evaluation.n (check ICTS map)

The so-called singular scientific and technical infrastructures (ICTS) are large installations, resources, facilities and services, unique in its kind, that are dedicated to cutting edge and high quality research and technological development, as well as to promote exchange, transmission and preservation of knowledge, technology transfer and innovation. Its main objective is provision to national and international scientific, technological and industrial community of essential scientific and technical infrastructure for the development of a scientific and technological research unique or exceptional in its genre, with a very high cost of investment and maintenance and whose importance and strategic nature justifies their availability for the whole R + D + i collective. Therefore, the ICTS are infrastructures of PUBLIC ownership, are UNIQUE and OPEN to competitive access to users of the whole research community in the public and private sector..

• Read More

Dr.Ramón Martínez Máñez has been appointed Scientific Director of the CIBER-BBN

Dr. Ramon Martinez Máñez, CIBER-BBN researcher at the Polytechnic University of Valencia, has been appointed Scientific Director of the CIBER-BBN in the CIBER Standing Committee of the Institute of Health Carlos III. Martinez-Máñez relieves Dr. Pablo Laguna, who occupied this position since February 2011.

Ramon Martinez Máñez is Principal Investigator of CIBER-BBN in the Group of Applied Molecular Chemistry Center of Molecular Recognition and Technological Development of the Polytechnic University of Valencia (UPV-ADM-IQMA).

“Some of the challenges and objectives in this new stage will be the promotion of competitiveness and quality of research, promote collaboration between groups both in the CIBER-BBN as other CIBER groups and promoting translational research, especially for clinical applications, “said Ramon Martinez Máñez.

The CIBER-BBN consists of 46 research groups, selected on the basis of scientific excellence, working mainly in three scientific programs: bioengineering and medical imaging; biomaterials and advanced therapies; and nanomedicine.

Martinez Máñez coordinator of BIOGATES, Intramural CIBER-BBN project, investigating new nanoparticles for diagnostics and drug delivery. The research group lines also fall within the Scientific Nanomedicine CIBER-BBN Program. This research group works with other CIBER-BBN groups in the development of nanoscale devices “molecular gates” for controlled drug release. Mesoporous silica nanoparticles with which they work are able to hold a charge in its pore system and deliver it when they applied a chemical, physical or biochemical stimulus. Other applications of these nanoparticles has been the selective delivery of cytotoxic for cancer cells, removal of bacteria or the release of certain drugs in senescent cells. Another of his lines of work is the development of probes for the detection of molecules of biological interest.

• Read More

You are here : Home / CIBER (Page 4)